Dr. Whitfield's Testimony Before the FDA General and Plastic Surgery Devices Panel
On March 25–26, 2019, Dr. Robert Whitfield testified before the FDA's Medical Devices Advisory Committee as President-Elect of the Aesthetic Surgery Education and Research Foundation (ASERF) and Vice Chair of the Breast Implant Illness Task Force — helping shape federal breast implant safety policy.
A Landmark Two-Day FDA Panel on Breast Implant Safety
The March 25–26, 2019 meeting of the FDA's General and Plastic Surgery Devices Panel was one of the most significant regulatory hearings in the history of breast implant medicine. Convened in response to mounting evidence linking breast implants to serious health conditions, the panel brought together surgeons, patient advocates, researchers, and manufacturers to address three interconnected concerns.
The hearing was prompted by international regulatory actions — including France's suspension of certain textured implants — and growing patient advocacy around conditions that had long been dismissed by the medical establishment. Over two full days, the panel heard testimony from nearly 40 ASPS member surgeons, dozens of patients, and invited expert witnesses including Dr. Whitfield.
The FDA used the panel's deliberations to inform its ongoing regulatory strategy for breast implants, ultimately leading to some of the most significant labeling changes in the device's history.
BIA-ALCL
Breast implant-associated anaplastic large cell lymphoma — a rare but serious T-cell lymphoma linked to textured implants. By the time of the hearing, 24 deaths had been reported. The panel reviewed case data and debated whether to recommend a market withdrawal of textured devices.
Breast Implant Illness (BII)
A constellation of systemic symptoms — chronic fatigue, brain fog, joint pain, autoimmune responses — reported by patients with breast implants. At the time of the hearing, BII was not officially recognized as a medical diagnosis. Dr. Whitfield was among the first to present funded research into its biological mechanisms.
Long-Term Safety Data & Registries
The panel also addressed the lack of long-term post-market surveillance data and the need for a National Breast Implant Registry (NBIR) to track outcomes. Testimony from ASPS and ASERF representatives shaped the FDA's approach to mandatory registry participation and informed consent.
What Dr. Whitfield Presented to the FDA Panel
Testifying in his dual capacity as President-Elect of ASERF and Vice Chair of the Breast Implant Illness Task Force, Dr. Whitfield brought both institutional authority and original research to the federal record.
Role & Authority
Dr. Whitfield testified as President-Elect of the Aesthetic Surgery Education and Research Foundation (ASERF) — the research arm of The Aesthetic Society — and as Vice Chair of the Breast Implant Illness Task Force. This dual role gave him both the institutional standing and the scientific credibility to present original research to the panel at a time when BII was still widely dismissed.
Research Presented
Dr. Whitfield outlined two ASERF-funded research initiatives:
- A qualitative pilot study using validated instruments (BREAST-Q) to assess BII symptom patterns in patients seeking explant surgery
- His own PCR-based analysis of explant capsule tissue for bacterial, fungal, and DNA markers — the precursor to his landmark 2024 biofilm study showing 29% contamination
The Argument
At a time when the medical establishment was divided on whether BII was a real condition, Dr. Whitfield argued before the federal panel that evidence-based research — not dismissal — was the appropriate response. He called for funded studies, standardized symptom assessment tools, and PCR-based tissue analysis to replace culture-only methods that miss the majority of bacterial contamination.
"In that capacity, I am working to identify evidence-based research to better understand breast implant illness and breast implant-associated ALCL. This research will then be used to educate the surgeons and benefit the patients associated.
— Dr. Robert Whitfield, FDA Hearing Transcript, p. 449· March 26, 2019
How the 2019 Hearing Shaped FDA Breast Implant Policy
The March 2019 hearing was a turning point in federal breast implant regulation. The testimony heard over those two days — from surgeons, patients, and researchers including Dr. Whitfield — directly informed a series of FDA actions that fundamentally changed how breast implants are regulated, labeled, and communicated to patients.
The FDA's subsequent actions represent the most significant regulatory changes to breast implant oversight since the devices were first approved. Dr. Whitfield's testimony, as a representative of ASERF's research mission, contributed to the scientific record that supported these changes.
New Labeling Recommendations
The FDA issued updated labeling recommendations for breast implant manufacturers, including requirements for a structured patient decision checklist and clearer communication of risks including BIA-ALCL and systemic symptoms.
Allergan Textured Implant Recall
The FDA requested Allergan recall its BIOCELL textured breast implants — the first such action in the device's history — citing the highest rate of BIA-ALCL among all textured implant types.
Black Box Warning Mandated
The FDA required all breast implant manufacturers to add a boxed warning — the strictest labeling available — to all breast implants, warning of BIA-ALCL, systemic symptoms, and other serious risks. This was the direct outcome the 2019 panel was convened to address.
Mandatory Informed Consent Checklist
The FDA now requires surgeons to provide patients with a standardized decision checklist before breast implant surgery, ensuring patients understand risks including BII, BIA-ALCL, and the possibility of future explant surgery. Dr. Whitfield's testimony on patient education directly supported this requirement.
FDA Webcast Recordings — Both Days
The full two-day hearing is preserved in the official FDA Yorkcast archive. Dr. Whitfield's testimony appears on Day 2 (March 26) beginning at transcript page 449.
Opening session covering BIA-ALCL epidemiology, international regulatory actions, manufacturer data presentations, and patient testimony. The panel reviewed case reports from the PROFILE registry and global surveillance data.
Open WebcastInvited expert testimony including Dr. Whitfield's presentation (p. 449), breast implant illness research, registry data from NBIR and PROFILE, and panel deliberations on labeling, informed consent, and long-term safety monitoring.
Open WebcastPrimary Sources & Federal Record
All materials from the March 25–26, 2019 FDA hearing are part of the permanent federal record. Dr. Whitfield's testimony is preserved in the official transcript at page 449.
Dr. Whitfield's Research & Authority
The FDA testimony was one chapter in a larger body of work. Dr. Whitfield's PCR capsule research — the largest in the world — has since been published in peer-reviewed journals and continues to shape the scientific understanding of breast implant illness.
You Deserve a Surgeon Who Prepares You, Not Just Operates on You.
Dr. Robert Whitfield has guided thousands of patients through surgical decisions with clarity, data, and a personalized plan. Your consultation is where that plan begins.
Not ready to book? Download the free Inflammation Support Guide to start your journey.